Ipilimumab

Ipilimumab

Summary

Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.

Background

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).⁵ Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.^1,2,5 Ipilimumab was developed by Bristol-Myers Squibb and Medarex.⁵

Ipilimumab was granted FDA approval on 25 March 2011.⁵

Protein Chemical Formula: C₆₅₇₂H₁₀₁₂₆N₁₇₃₄O₂₀₈₀S₄₀

Protein Average Weight: 148000.0 Da